Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

BioVersys AG

The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology it will be possible to restore the efficacy of established antibiotics. BioVersys addresses the high unmet medical need for new treatments of life-threatening bacterial infections that emerged in recent years due to antibiotic resistance. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is on Nosocomial Infections (hospital infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille BioVersys aims to develop an effective treatment against *


Period Start 2008-09-19 splitoff
  Predecessor ETH Zürich, Dept. of Biosystems Science and Engineering (D-BSSE, Basel)
Product Industry antibiotic
Persons Person Gitzinger, Marc (BioVersys 2008– CEO + Co-founder)
  Person 2 Tigges, Marcel (BioVersys 2008– CSO + Co-founder)
Region Region Basel BS
  Country Switzerland
  Street 60c Hochbergerstr.
Technologiepark Basel, 3rd Floor
  City 4057 Basel BS
  Tel +41-61-387-3289
    Address record changed: 2020-12-02
Basic data Employees A: 1 to 10 (2011-04-28)
    * Document for �About Section�: 
Record changed: 2021-06-02


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for BioVersys AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top